|
|
Other links at Articles > Allergy and Clinical Immunology |
| 1. |
Encouraging Phase 2b Results With Oral Laquinimod in MS
|
|
|
Results of a phase 2b trial of laquinimod, an investigational oral treatment for MS, showed the higher dose of 0.6 mg/day was well tolerated and significantly reduced disease activity on MRI. Phase 3 trials are under way. Medscape Medical News
|
| 2. |
Electronic Nose Identifies Breath From Patients With Asthma
|
|
|
An electronic nose that senses volatile organic compounds (VOCs) in exhaled breath can distinguish patients with asthma from normal controls, according to a report in the October Journal of Allergy and Clinical Immunology. Reuters Health Information
|
| 5. |
New Anti-IL-5 Agent Cuts Need for Prednisone in Hypereosinophilic Syndrome
|
|
|
The investigational anti-interleukin-5 (anti-IL-5) monoclonal antibody mepolizumab (GlaxoSmithKline) caused a sharp drop in blood eosinophil count in nearly every patient with hypereosinophilic syndrome who received it. Mepolizumab also reduced the need for corticosteroids. Reuters Health Information
|
|
|
